House Dust Mite Allergy - Market Insights, Epidemiology and Market Forecast to 2027

World News: . []

Dublin, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The drug pipelines has been added to offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of House Dust Mite Allergy from 2016 to 2027 segmented by the US, EU-5 countries and Japan.

The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.The House Dust Mite Allergy market report gives the thorough understanding of the House Dust Mite Allergy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, treatment algorithms and treatment guidelines in the US, Europe, and Japan.

The disease epidemiology covered in the report is segmented into two parts: Total Prevalent Population of Respiratory Allergy and Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan]. According to the publisher, the prevalent cases of House Dust Mite Induced Respiratory Allergy was 50,703,100 in 2016 in 7MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of House Dust Mite Allergy with 69,310,852 prevalent cases in 2016.House Mite Allergy is a hypersensitive (IgE mediated) reaction to proteins in the excrement of dust mites. These proteins can cause an allergic reaction in the respiratory passages causing the symptoms of hay fever and asthma. It can often aggravate atopic dermatitis (eczema) in people who have this problem, causing facial eczema that can be difficult to treat. Odactra by Merck Sharp & Dohme Corp. and Actair by Shionogi & Co. are currently approved therapies for House Dust Mite Allergies. The report provides global market share of House Dust Mite Allergy i.e., 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)] and Japan. In 2016, global market size of House Dust Mite Allergy was USD 258 million and, is expected to grow during the forecast period of 2018-2027.The region-wise market size for House Dust Mite Allergy in US, EU-5 countries (Germany, France, Italy, Spain and the U.K.) and Japan shows highest market size in US, followed by Germany, the lowest being in the Spain.

For more information about this drug pipelines report visit


CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Allergy Drugs

More news and information about Research and Markets

Published By:

Globe Newswire: 09:07 GMT Thursday 6th December 2018

Published: .

Search for other references to "house" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us